Roche’s Alzheimer antibody granted U.S. FDA Breakthrough Therapy Designation
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
The agreement will sharpen Cigna's focus on the growth path for its rapidly expanding global health portfolio
This opens up a huge market for the company’s Magnezis implants in India
Early-stage research suggests the potential to prevent and treat all dengue serotypes and builds on Johnson & Johnson's work to advance science against emerging and entrenched global public health threats
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
The transaction is anticipated to close in the first quarter of 2022
The filing includes data from PROVENT Phase III trial showing 77% reduction in risk of developing symptomatic Covid-19 with a long-acting antibody combination (non-vaccine)
Ectosense’s NightOwl is a leading cloud-connected home sleep apnea test
Cipla is a leading global pharma company
Subscribe To Our Newsletter & Stay Updated